Real-World Clinical Management Of Patients With Hemophilia And Inhibitors: Effectiveness And Safety Of Apcc In Patients With > 18 Months' Follow-Up In The Feiba Global Outcome Study (Feiba Go)

Introduction: The primary objective of the FEIBA Global Outcome study (FEIBA GO) is to describe the long-term, real-world effectiveness and safety of activated prothrombin complex concentrate (aPCC; Feiba®, Baxalta Inc, a Takeda company, Lexington, MA, USA) for preventing and managing bleeding in patients with congenital hemophilia A or B with inhibitors (PwHI) across different clinical settings. This interim >18-month analysis corresponds to the report of May 2019.